Combination therapy with 211 At-labeled RGD peptide and immune checkpoint inhibitor (anti-CTLA-4 antibody) resulted in greater tumor growth suppression and improved survival compared to monotherapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback